Literature DB >> 27053532

A genome editing primer for the hematologist.

Megan D Hoban1, Daniel E Bauer1.   

Abstract

Gene editing enables the site-specific modification of the genome. These technologies have rapidly advanced such that they have entered common use in experimental hematology to investigate genetic function. In addition, genome editing is becoming increasingly plausible as a treatment modality to rectify genetic blood disorders and improve cellular therapies. Genome modification typically ensues from site-specific double-strand breaks and may result in a myriad of outcomes. Even single-strand nicks and targeted biochemical modifications that do not permanently alter the DNA sequence (epigenome editing) may be powerful instruments. In this review, we examine the various technologies, describe their advantages and shortcomings for engendering useful genetic alterations, and consider future prospects for genome editing to impact hematology.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2016        PMID: 27053532      PMCID: PMC4882802          DOI: 10.1182/blood-2016-01-678151

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  162 in total

1.  The zinc finger nuclease monopoly.

Authors:  Christopher Thomas Scott
Journal:  Nat Biotechnol       Date:  2005-08       Impact factor: 54.908

Review 2.  Double-strand break-induced recombination in eukaryotes.

Authors:  F Osman; S Subramani
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1998

3.  Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects.

Authors:  Bin Shen; Wensheng Zhang; Jun Zhang; Jiankui Zhou; Jianying Wang; Li Chen; Lu Wang; Alex Hodgkins; Vivek Iyer; Xingxu Huang; William C Skarnes
Journal:  Nat Methods       Date:  2014-03-02       Impact factor: 28.547

4.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

5.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.

Authors:  Ayal Hendel; Rasmus O Bak; Joseph T Clark; Andrew B Kennedy; Daniel E Ryan; Subhadeep Roy; Israel Steinfeld; Benjamin D Lunstad; Robert J Kaiser; Alec B Wilkens; Rosa Bacchetta; Anya Tsalenko; Douglas Dellinger; Laurakay Bruhn; Matthew H Porteus
Journal:  Nat Biotechnol       Date:  2015-06-29       Impact factor: 54.908

6.  Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs.

Authors:  Ning Sun; Huimin Zhao
Journal:  Biotechnol Bioeng       Date:  2013-08-26       Impact factor: 4.530

7.  A mechanism for the suppression of homologous recombination in G1 cells.

Authors:  Alexandre Orthwein; Sylvie M Noordermeer; Marcus D Wilson; Sébastien Landry; Radoslav I Enchev; Alana Sherker; Meagan Munro; Jordan Pinder; Jayme Salsman; Graham Dellaire; Bing Xia; Matthias Peter; Daniel Durocher
Journal:  Nature       Date:  2015-12-09       Impact factor: 49.962

8.  Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining.

Authors:  Marcello Maresca; Victor Guosheng Lin; Ning Guo; Yi Yang
Journal:  Genome Res       Date:  2012-11-14       Impact factor: 9.043

9.  megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering.

Authors:  Sandrine Boissel; Jordan Jarjour; Alexander Astrakhan; Andrew Adey; Agnès Gouble; Philippe Duchateau; Jay Shendure; Barry L Stoddard; Michael T Certo; David Baker; Andrew M Scharenberg
Journal:  Nucleic Acids Res       Date:  2013-11-26       Impact factor: 16.971

10.  Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors.

Authors:  Jianbin Wang; Colin M Exline; Joshua J DeClercq; G Nicholas Llewellyn; Samuel B Hayward; Patrick Wai-Lun Li; David A Shivak; Richard T Surosky; Philip D Gregory; Michael C Holmes; Paula M Cannon
Journal:  Nat Biotechnol       Date:  2015-11-09       Impact factor: 54.908

View more
  11 in total

1.  Acoustofluidic sonoporation for gene delivery to human hematopoietic stem and progenitor cells.

Authors:  Jason N Belling; Liv K Heidenreich; Zhenhua Tian; Alexandra M Mendoza; Tzu-Ting Chiou; Yao Gong; Natalie Y Chen; Thomas D Young; Natcha Wattanatorn; Jae Hyeon Park; Leonardo Scarabelli; Naihao Chiang; Jack Takahashi; Stephen G Young; Adam Z Stieg; Satiro De Oliveira; Tony Jun Huang; Paul S Weiss; Steven J Jonas
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-01       Impact factor: 11.205

Review 2.  CRISP Points on Establishing CRISPR-Cas9 In Vitro Culture Experiments in a Resource Constraint Haematology Oncology Research Lab.

Authors:  Jhumki Das; Prateek Bhatia; Aditya Singh
Journal:  Indian J Hematol Blood Transfus       Date:  2018-09-17       Impact factor: 0.900

3.  Characterization of Gene Alterations following Editing of the β-Globin Gene Locus in Hematopoietic Stem/Progenitor Cells.

Authors:  Joseph Long; Megan D Hoban; Aaron R Cooper; Michael L Kaufman; Caroline Y Kuo; Beatriz Campo-Fernandez; Dianne Lumaquin; Roger P Hollis; Xiaoyan Wang; Donald B Kohn; Zulema Romero
Journal:  Mol Ther       Date:  2017-11-09       Impact factor: 11.454

Review 4.  Studying disorders of vertebrate iron and heme metabolism using zebrafish.

Authors:  Lisa N van der Vorm; Barry H Paw
Journal:  Methods Cell Biol       Date:  2016-12-09       Impact factor: 1.441

Review 5.  Pathophysiology and recent therapeutic insights of sickle cell disease.

Authors:  Firdosh Shah; Mitesh Dwivedi
Journal:  Ann Hematol       Date:  2020-03-10       Impact factor: 3.673

Review 6.  Gene therapy for sickle cell disease: moving from the bench to the bedside.

Authors:  Allistair A Abraham; John F Tisdale
Journal:  Blood       Date:  2021-09-16       Impact factor: 25.476

Review 7.  Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.

Authors:  Baixin Ye; Creed M Stary; Qingping Gao; Qiongyu Wang; Zhi Zeng; Zhihong Jian; Lijuan Gu; Xiaoxing Xiong
Journal:  J Immunol Res       Date:  2017-01-02       Impact factor: 4.818

Review 8.  Engineering chimeric antigen receptor-T cells for cancer treatment.

Authors:  Baixin Ye; Creed M Stary; Xuejun Li; Qingping Gao; Chunsheng Kang; Xiaoxing Xiong
Journal:  Mol Cancer       Date:  2018-02-15       Impact factor: 27.401

9.  Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells.

Authors:  Malika Hale; Baeckseung Lee; Yuchi Honaker; Wai-Hang Leung; Alexandra E Grier; Holly M Jacobs; Karen Sommer; Jaya Sahni; Shaun W Jackson; Andrew M Scharenberg; Alexander Astrakhan; David J Rawlings
Journal:  Mol Ther Methods Clin Dev       Date:  2017-01-10       Impact factor: 6.698

10.  Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia.

Authors:  Shuqian Xu; Kevin Luk; Qiuming Yao; Anne H Shen; Jing Zeng; Yuxuan Wu; Hong-Yuan Luo; Christian Brendel; Luca Pinello; David H K Chui; Scot A Wolfe; Daniel E Bauer
Journal:  Blood       Date:  2019-01-31       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.